ALTASCIENCES
9.12.2021 17:02:06 CET | Business Wire | Press release
Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection.
The first of several clinical trials to characterize XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors, its purpose is to determine whether the increased bioavailability of oxypurinol demonstrated for this formulation in preclinical studies will be replicated in humans.
Dr. Allen Davidoff, President and CEO stated, “XORTX is pleased to be starting work with Altasciences as we initiate the characterization of our novel, proprietary formulations of xanthine oxidase inhibitors. This study marks the first of several clinical trials planned for the next year and an exciting opportunity to advance our kidney disease programs through preliminary characterization, followed by late stage registration trials. ”
“With a pressing need for better therapeutic options and a global prevalence of kidney disease, we are proud to partner with XORTX for such an important study. We look forward to supporting this innovative company in their goal of bringing a valuable new treatment to the next stage, and getting better drugs to the people who need them, faster, ” stated Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences.
Altasciences offers a seamless drug development solution that allows sponsors to work with a single, integrated CRO/CDMO in support of early-phase research, from lead candidate selection to preclinical testing to clinical proof of concept in the most time- and cost-efficient way possible.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005134/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Expands Combo Antenna Portfolio with Rugged Multi-network Solutions for Demanding IoT Deployments25.6.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has expanded its external antenna portfolio with four new combo antennas designed to simplify deployment of connected devices across smart cities, fleet management, industrial automation, utilities, public safety and transport applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625825719/en/ Quectel expands combo antenna portfolio with rugged multi-network solutions for demanding IoT deployments The new YEMA206J1AM, YEMA301J1AM, YEMN308L1BM and YENA00L5AH antennas combine cellular, Wi-Fi and GNSS technologies in rugged, compact form factors that help engineers accelerate product development while ensuring reliable connectivity in demanding outdoor and industrial environments. Featuring IP67-rated enclosures, high inter-antenna isolation, flexible mounting options and support for multiple wireless standards, the antennas provide a versatile so
Safe Software Appoints Nabil Lodey as Its First EMEA Senior Executive to Drive Regional Expansion25.6.2026 10:00:00 CEST | Press release
Nabil Lodey joins as VP EMEA to lead Safe Software's expansion across the region, bringing deep geospatial industry expertise and an established network across the partner and customer ecosystem. Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, today announced the appointment of Nabil Lodey as VP EMEA, where he will drive growth in the company's presence and customer base across the region. His appointment builds directly on Safe's operational expansion into the UK and Ireland, announced in June 2025. Nabil joins Safe from 1Spatial, a long-standing Safe partner and FME reseller, where he served as Managing Director for the UK and Ireland. He brings a deep, first-hand understanding of Safe's business and of the FME Platform, having worked closely with the technology and its customer base. That familiarity positions him to further accelerate Safe's regional expansion plan while deepening the company's commitment to support clients and partn
Floward Scales Customer Service to Handle 13x Peak Demand With Infobip AgentOS25.6.2026 10:00:00 CEST | Press release
AI-powered customer service enables seamless experiences during peak seasons Global AI-first cloud communications platform Infobip has partnered with Floward, the leading online flower and gifting company in the Middle East and the UK, to transform customer service using AI agents on Infobip’s AgentOS platform. By moving beyond traditional rule-based chatbots to agentic AI, Floward now handles up to 13x higher peak-day conversation volumes while maintaining fast response times and high customer satisfaction. As a same-day delivery business built around major occasions such as Mother’s Day, Valentine’s Day, and Ramadan, Floward experiences intense seasonal demand spikes. Working with Infobip’s AI consultants, Floward redesigned its customer journeys on Infobip AgentOS, deploying a multi-agent system that intelligently routes conversations to specialized AI agents for tasks such as address collection, FAQs, and order changes, with seamless escalation to live agents when needed. A key inn
ISC 2026: KAYTUS Unveils Gigawatt-Scale AI Infrastructure and Intelligent Management to Empower Europe’s AI Future25.6.2026 09:02:00 CEST | Press release
End-to-end, fully factory-prefabricated modular AI Factory deployment in just a few months, with full-stack intelligent management from GPU to rack, to the entire data center. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, unveiled two core solutions at ISC 2026, designed for next-generation AI data centers: a gigawatt-scale, fully prefabricated containerized liquid-cooled data center solution and KSManage Ultra, an intelligent operations management platform for AI Factories. Together, the solutions target the escalating efficiency, performance, scalability, and reliability requirements of AI-era infrastructure, enabling faster deployment, optimized thermal management, and unified operations across large-scale AI computing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625809392/en/ KAYTUS prefabricated containerized liquid cooled data center solution The KAYTUS gigawatt-scale
LR Health & Beauty SE Successfully Completes Financial Realignment – Strong Foundation for Growth and Long-Term Partnerships25.6.2026 09:00:00 CEST | Press release
Successful completion of the financial realignment enables full focus on growth and further strengthening operational excellence Planned investments in production and logistics will enhance efficiency, flexibility, and delivery capabilities Further international growth, including expansion into new markets, targeted LR Health & Beauty SE, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, has successfully completed its financial realignment, establishing the foundation for the company’s stable and forward-looking development. With the achievement of the final milestone, an intensive and demanding process has been successfully concluded. LR has fundamentally realigned its financing structure and significantly strengthened its capital base. An initial financing tranche of EUR 10 million was provided at the end of March, followed by a second tranche of the same amount in June. Jörg Körfer, CEO of LR Health & Beauty SE, comments: “The pas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom